Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | DPP4 | P27487 | 2/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9762253 | 0.82 | TAAR1 (0.58) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Phenethylamine SCHEMBL3135462 | 0.78 | TAAR1 (0.64) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL1047500 | 0.77 | TAAR1 (0.89) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Phenethylamine SCHEMBL1799333 | 0.77 | HTR2A (1.00) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Phenethylamine SCHEMBL1331271 | 0.77 | — | — | |
| Phenethylamine SCHEMBL27634208 | 0.77 | HTR2A (1.00) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Phenethylamine SCHEMBL1330939 | 0.77 | — | — | |
| Phenethylamine SCHEMBL1332244 | 0.77 | — | — | |
| Phenethylamine SCHEMBL968 | 0.77 | — | — | |
| SCHEMBL239938 | 0.76 | DPP4 (1.00) | TAAR1HTR2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964730-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-04-30 | — | — | US | disclosed |
| CN-100465158-C | Amino-substituted ethylamino beta2-adrenergic receptor agonists | THERAVANCE INC (US) | 2009-03-04 | — | — | CN | disclosed |
| CN-1856465-A | Amino-substituted ethylamino beta2-adrenergic receptor agonists | THERAVANCE INC (US) | 2006-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | TAAR1 60/4885HTR2A 66/4885CYP2A6 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.